Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

Background: Despite progress in treatment, many metastatic renal cell carcinoma (mRCC) patients still experience progression after first-line tyrosine kinase inhibitor (TKI), necessitating effective second-line options. While guidelines endorse combination therapies, accessibility limitations often...

Full description

Saved in:
Bibliographic Details
Main Authors: Musa Barış Aykan, Hatice Bölek, Emre Yekedüz, Elif Sertesen, Deniz Tural, Cengiz Karaçin, Mehmet Ali Nahit Şendur, Gökhan Uçar, Çağatay Arslan, Selver Işık, Saadet Sim, Özlem Nuray Sever, Bekir Hacıoğlu, Sema Sezgin Göksu, Mustafa Özgüroğlu, Nuri Karadurmuş, Yüksel Ürün
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251331540
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items